Glaxosmithkline Pharmaceuticals Limited · NSE:GLAXO
Glaxosmithkline Pharmaceuticals — Q3 FY26 Earnings Presentation
9 slides from Glaxosmithkline Pharmaceuticals's earnings presentation, Feb 9, 2026
Slide 1: Presentation of Analyst / Institutional Investor Meetings
GlaxoSmithKline Pharmaceuticals Limited GSK House, Dr. Annie Besant Road, Worli, Mumbai - 400 030 Tel No: +91 22 2495 9595 Fax No: +91 22 2495 9494 Web: www.gsk-india.com Email: askus@gsk.com 9th February 2026 To, BSE LIMITED THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Phiroze Jeejeebhoy Towers Exc
Slide 2: GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited 9th February, 2026 gsk.com
Slide 3: Bhushan Akshikar, Managing Director; Juby Chandy, Chief Financial Officer
Bhushan Akshikar, Managing Director Mr. Bhushan Akshikar has been the MD of GSK India since Q3 2022. He brings over 14 years of leadership experience in key roles within GSK spanning across India, Middle East, Russia CIS & Africa region. Prior to joining GSK, Bhushan spent 15 years with Johnson & Jo
Slide 4: GSK India's commercial ambition: focus, innovate and agile
GSK India’s commercial ambition is driven by focus, innovation and agility, underpinned by continuous cultural transformation Our Portfolio 2 Agile to be ambitious Test, learn and adapt to create adult IZ as a 3 Innovate General Medicines category for Shingles Anti-infectives, dermatology, pain, VMN
Slide 5: Indian Pharma Market grew 11.8% in Q3FY26
Indian Pharma Market grew at 11.8% to reach ~₹662B in Q3FY26 ; GSK rep market grew at 8.6%, in-line with acute market Acute market grew 8.6% after a Amongst GSK’s key therapies GSK’s rep market grew at 8.6% muted Q2, driven by price and new Vaccines, Hormones, VMN and driven by the growth of its key
Slide 6: GSK grew 10.5% in-market across Gen Meds, Vaccines and Specialty
GSK grew by 10.5% in-market driven by above market performance across Gen Meds, Vaccines & Specialty GENERAL MEDICINES VACCINES SPECIALTY Gen Meds grew at 9% (Unit EI 102) in Established Vaccines continues to lead Building equity in the 1 2 4 market; key brands delivered competitive the overall Vx m
Slide 7: Financial Highlights: Q3 FY 25-26 (Standalone)
Financial Highlights : Q3 FY 25-26 (Standalone) Revenue EBITDA PAT (before exceptional) ₹368cr ₹277cr ₹1023cr Margin: 35.9% (+520bps) Growth +8.1% Margin: 27.3% (+290bps) Growth +26.7% Growth +21.3% Revenue growth +8.1% EBITDA margin +520 bps (YoY) PAT +290 bps (YoY) ▪ General Medicine sales growth
Slide 8: Innovation: Consistent competitive performance and profitability improvement
Consistent competitive performance & profitability improvement with portfolio transformation Improving profitability 34.4 35.9 Portfolio transformation 34.3 31.9 28.5 30.7 31.2 28.3 28 27 Oncology launches 24.3 Q3 FY22 Q3 FY23 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 I
Slide 9: End of Presentation
gsk.com End of Presentation
GlaxoSmithKline Pharmaceuticals — Q3 FY26 Earnings Presentation on 6ix